Human papillomavirus vaccine - Oryx

Drug Profile

Human papillomavirus vaccine - Oryx

Alternative Names: P16_37-63; p16INK4a peptide vaccine; p16INK4a-37-63; Vaccine p16; VicOryx

Latest Information Update: 13 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Heidelberg
  • Developer Oryx GmbH & Co
  • Class Cancer vaccines; Papillomavirus vaccines
  • Mechanism of Action Cyclin-dependent kinase inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Cancer

Most Recent Events

  • 01 May 2017 Oryx GmbH completes a phase I/IIa trial in Cancer (Late-stage disease, Combination therapy) in Germany (NCT02526316) (Oryx pipeline, August 2017)
  • 07 Jan 2016 Human papillomavirus vaccine is available for licensing before Jan 2016. http://www.oryx-medicine.com
  • 15 Sep 2015 Efficacy data from a phase I/II trial in Cancer released by Oryx
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top